CA2614392A1 - Traitement de patients cancereux presentant une activation du mecanisme de pompe d'efflux de la glycoproteine p - Google Patents

Traitement de patients cancereux presentant une activation du mecanisme de pompe d'efflux de la glycoproteine p Download PDF

Info

Publication number
CA2614392A1
CA2614392A1 CA002614392A CA2614392A CA2614392A1 CA 2614392 A1 CA2614392 A1 CA 2614392A1 CA 002614392 A CA002614392 A CA 002614392A CA 2614392 A CA2614392 A CA 2614392A CA 2614392 A1 CA2614392 A1 CA 2614392A1
Authority
CA
Canada
Prior art keywords
glycoprotein
dye
efflux
cells
pump inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002614392A
Other languages
English (en)
Inventor
Branimir Sikic
Daniel Hoth
David Socks
Scott Glenn
John Marcelletti
Michael J. Walsh
Pratik S. Multani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANISA PHARMACEUTICALS Inc
Original Assignee
Kanisa Pharmaceuticals, Inc.
Branimir Sikic
Daniel Hoth
David Socks
Scott Glenn
John Marcelletti
Michael J. Walsh
Pratik S. Multani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/418,399 external-priority patent/US20070009535A1/en
Priority claimed from US11/417,984 external-priority patent/US20070009533A1/en
Priority claimed from US11/418,323 external-priority patent/US20070009534A1/en
Application filed by Kanisa Pharmaceuticals, Inc., Branimir Sikic, Daniel Hoth, David Socks, Scott Glenn, John Marcelletti, Michael J. Walsh, Pratik S. Multani filed Critical Kanisa Pharmaceuticals, Inc.
Publication of CA2614392A1 publication Critical patent/CA2614392A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002614392A 2005-07-06 2006-06-30 Traitement de patients cancereux presentant une activation du mecanisme de pompe d'efflux de la glycoproteine p Abandoned CA2614392A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US69691305P 2005-07-06 2005-07-06
US60/696,913 2005-07-06
US72682705P 2005-10-14 2005-10-14
US60/726,827 2005-10-14
US11/418,399 US20070009535A1 (en) 2005-07-06 2006-05-03 Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US11/418,323 2006-05-03
US11/417,984 2006-05-03
US11/418,399 2006-05-03
US11/417,984 US20070009533A1 (en) 2005-07-06 2006-05-03 Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US11/418,323 US20070009534A1 (en) 2005-07-06 2006-05-03 Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
PCT/US2006/026035 WO2007008499A1 (fr) 2005-07-06 2006-06-30 Traitement de patients cancereux presentant une activation du mecanisme de pompe d'efflux de la glycoproteine p

Publications (1)

Publication Number Publication Date
CA2614392A1 true CA2614392A1 (fr) 2007-01-18

Family

ID=37637469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002614392A Abandoned CA2614392A1 (fr) 2005-07-06 2006-06-30 Traitement de patients cancereux presentant une activation du mecanisme de pompe d'efflux de la glycoproteine p

Country Status (4)

Country Link
EP (1) EP1899728A4 (fr)
AU (1) AU2006269501A1 (fr)
CA (1) CA2614392A1 (fr)
WO (1) WO2007008499A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102217010B1 (ko) * 2018-01-26 2021-02-18 재단법인 대구경북첨단의료산업진흥재단 칼슘 채널 억제제 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773280A (en) * 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US6277655B1 (en) * 1994-10-13 2001-08-21 Solvo Biotechnology Assay and reagent kit for evaluation of multi-drug resistance in cells
US6610489B2 (en) * 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions

Also Published As

Publication number Publication date
WO2007008499A1 (fr) 2007-01-18
EP1899728A1 (fr) 2008-03-19
EP1899728A4 (fr) 2009-03-25
AU2006269501A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
US20070009533A1 (en) Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
Ng et al. Expression of P-glycoprotein in hepatocellular carcinoma: a determinant of chemotherapy response
RU2480211C2 (ru) Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
AU2018214086B2 (en) Use of eribulin in the treatment of breast cancer
US20080214606A1 (en) Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
JP2022082565A (ja) がんを処置するための方法
US20070009535A1 (en) Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20220387618A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US20070010466A1 (en) Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US11376259B2 (en) Targeted treatment of mature T-cell lymphoma
WO2015177184A1 (fr) Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
US20070009532A1 (en) Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070009534A1 (en) Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
CA2614392A1 (fr) Traitement de patients cancereux presentant une activation du mecanisme de pompe d'efflux de la glycoproteine p
WO2016184793A1 (fr) Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr
WO2007008490A2 (fr) Zosuquidar, daunorubicine et cytarabine pour le traitement du cancer
CA3180522A1 (fr) Procedes therapeutiques pour la prevention des metastases et des recidives tumorales
Xu et al. In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
WO2023192291A2 (fr) Composés indolium pour le traitement du cancer
Fröbom Translational Investigations of Novel and Current Antitumoral Therapies in Gastrointestinal Stromal Tumors
CN111840274A (zh) 巴伐洛霉素a1在制备增强7-脱氧水仙环素的抗肝癌活性药物中的应用
WO2007008479A1 (fr) Traitement de patients atteints de cancer a l'aide d'un conjugue de calicheamicine et d'anticorps en combinaison avec du zosuquidar
WO2012011485A1 (fr) Méthode de prédiction de l'effet thérapeutique d'une chimiothérapie sur les patientes atteintes d'un cancer du sein
Gerrard Modulation of P-glycoprotein by Zosuquidar Trihydrochloride

Legal Events

Date Code Title Description
FZDE Discontinued